The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers
The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and d...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1016059/full |
| _version_ | 1828106705145167872 |
|---|---|
| author | Rong Fan Nathan De Beule Anke Maes Elke De Bruyne Eline Menu Karin Vanderkerken Ken Maes Karine Breckpot Kim De Veirman |
| author_facet | Rong Fan Nathan De Beule Anke Maes Elke De Bruyne Eline Menu Karin Vanderkerken Ken Maes Karine Breckpot Kim De Veirman |
| author_sort | Rong Fan |
| collection | DOAJ |
| description | The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and drug resistance. Based on their morphology and phenotype, MDSC are commonly subdivided into polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC), both characterized by their immunosuppressive function. The phenotype, function and prognostic value of MDSC in hematological cancers has been intensively studied; however, the therapeutic targeting of this cell population remains challenging and needs further investigation. In this review, we will summarize the prognostic value of MDSC and the different attempts to target MDSC (or subtypes of MDSC) in hematological cancers. We will discuss the benefits, challenges and opportunities of using MDSC-targeting approaches, aiming to enhance anti-tumor immune responses of currently used cellular and non-cellular immunotherapies. |
| first_indexed | 2024-04-11T10:20:23Z |
| format | Article |
| id | doaj.art-4a066c1d34e84d5fab2ce817a5f72403 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T10:20:23Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-4a066c1d34e84d5fab2ce817a5f724032022-12-22T04:29:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.10160591016059The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancersRong Fan0Nathan De Beule1Anke Maes2Elke De Bruyne3Eline Menu4Karin Vanderkerken5Ken Maes6Karine Breckpot7Kim De Veirman8Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, BelgiumDepartment of Clinical Hematology, Universitair Ziekenhuis Brussel, Brussels, BelgiumDepartment of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, BelgiumDepartment of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, BelgiumDepartment of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, BelgiumDepartment of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, BelgiumCenter for Medical Genetics, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, BelgiumLaboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences Vrije Universiteit Brussel, Brussels, BelgiumDepartment of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, BelgiumThe success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and drug resistance. Based on their morphology and phenotype, MDSC are commonly subdivided into polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC), both characterized by their immunosuppressive function. The phenotype, function and prognostic value of MDSC in hematological cancers has been intensively studied; however, the therapeutic targeting of this cell population remains challenging and needs further investigation. In this review, we will summarize the prognostic value of MDSC and the different attempts to target MDSC (or subtypes of MDSC) in hematological cancers. We will discuss the benefits, challenges and opportunities of using MDSC-targeting approaches, aiming to enhance anti-tumor immune responses of currently used cellular and non-cellular immunotherapies.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1016059/fullhematological cancersmyeloid-derived suppressor cellsimmunotherapiesmultiple myelomaleukemialymphoma |
| spellingShingle | Rong Fan Nathan De Beule Anke Maes Elke De Bruyne Eline Menu Karin Vanderkerken Ken Maes Karine Breckpot Kim De Veirman The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers Frontiers in Immunology hematological cancers myeloid-derived suppressor cells immunotherapies multiple myeloma leukemia lymphoma |
| title | The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers |
| title_full | The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers |
| title_fullStr | The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers |
| title_full_unstemmed | The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers |
| title_short | The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers |
| title_sort | prognostic value and therapeutic targeting of myeloid derived suppressor cells in hematological cancers |
| topic | hematological cancers myeloid-derived suppressor cells immunotherapies multiple myeloma leukemia lymphoma |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1016059/full |
| work_keys_str_mv | AT rongfan theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT nathandebeule theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT ankemaes theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT elkedebruyne theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT elinemenu theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT karinvanderkerken theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT kenmaes theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT karinebreckpot theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT kimdeveirman theprognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT rongfan prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT nathandebeule prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT ankemaes prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT elkedebruyne prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT elinemenu prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT karinvanderkerken prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT kenmaes prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT karinebreckpot prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers AT kimdeveirman prognosticvalueandtherapeutictargetingofmyeloidderivedsuppressorcellsinhematologicalcancers |